Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Shionogi

Status and phase: Completed; Phase 3

Conditions: Opioid-induced Constipation

Treatments: Drug: Naldemedine; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01993940

2013-002948-91 (EudraCT Number)

1315V9232

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.

Enrollment: 553 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects aged 18 to 80 years inclusive at the time of informed consent
• Subjects must have non-malignant chronic pain treated with opioids and must have opioid-induced constipation (OIC)
• Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate
• Subjects must not be currently using laxatives or must be willing to discontinue laxative use at Screening and must be willing to use only the rescue laxatives provided throughout the study duration
• Subjects must meet opioid-induced constipation criteria based on the Bowel Movement and Constipation Assessment (BMCA) Diary

Exclusion criteria

• Evidence of significant structural abnormalities of the gastrointestinal (GI) tract
• Evidence of active medical diseases affecting bowel transit
• History or presence of pelvic disorders that may be a cause of constipation
• Surgery (except for minor procedures) within 60 days of Screening
• History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g., mechanical GI obstruction)
• Subjects who have never taken laxatives for the treatment of OIC
• History of active treatment for cancer within the last 2 years (except for basal cell or squamous cell carcinoma of the skin that have been successfully resected) or tamoxifen [Nolvadex®] and raloxifene [Evista®] when being used for prevention of breast cancer
• Current use of any prohibited medication including opioid antagonists, partial agonists, or mixed agonists/antagonists

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

553 participants in 2 patient groups, including a placebo group

Naldemedine

Experimental group

Description:

Participants received 0.2 mg naldemedine orally once daily for 12 weeks.

Treatment:

Drug: Naldemedine

Placebo

Placebo Comparator group

Description:

Participants received matching placebo orally once daily for 12 weeks.

Treatment:

Drug: Placebo